ITRM
NASDAQ · Pharmaceuticals
Iterum Therapeutics Plc
$0.17
0.00 (-1.35%)
Financial Highlights (FY 2025)
Revenue
2.84M
Net Income
737.1K
Gross Margin
39.4%
Profit Margin
25.9%
Rev Growth
+5.6%
D/E Ratio
0.35
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 39.4% | 39.4% | 39.4% |
| Operating Margin | 26.1% | 31.9% | 29.0% |
| Profit Margin | 25.9% | 23.7% | 19.6% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.84M | 2.52M | 2.36M |
| Gross Profit | 1.12M | 992.1K | 930.6K |
| Operating Income | 740.6K | 802.8K | 684.7K |
| Net Income | 737.1K | 595.8K | 463.7K |
| Gross Margin | 39.4% | 39.4% | 39.4% |
| Operating Margin | 26.1% | 31.9% | 29.0% |
| Profit Margin | 25.9% | 23.7% | 19.6% |
| Rev Growth | +5.6% | +6.9% | +16.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 3.14M | 2.38M | 2.35M |
| Total Equity | 9.04M | 8.10M | 7.99M |
| D/E Ratio | 0.35 | 0.29 | 0.29 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.27M | 1.08M | 1.08M |
| Free Cash Flow | 617.3K | 603.4K | 596.2K |